HoldsUp

Nigel A. Calcutt

Nigel A. Calcutt is a researcher specializing in the study and treatment of peripheral nervous system disorders. His research primarily focuses on the mechanisms and therapeutics of diabetic peripheral neuropathy, including the use of muscarinic receptor antagonists to stimulate nerve repair and mitochondrial function. He has also co-authored studies evaluating diagnostic and physiological measures of neuropathy, such as rate-dependent depression of the Hoffmann reflex and nerve fiber density.

19 claims checked on air: 2 overstated 14 supported 3 unverified

What they said on air - unverified

1 citing their own research

0:06:16unverifiedvery lowExciting Developments in the Treatment of Peripheral Neuropa

Worldwide estimates of peripheral neuropathy prevalence range from 250 million to 500 million people.

"The worldwide incidence is difficult to estimate, but there've been estimates 250, 500 million people." (said at 0:06:16)

No published record matching the claim that worldwide estimates of peripheral neuropathy prevalence range from 250 million to 500 million people was located; this does not prove the claim false.

0:40:40unverifiedvery lowExciting Developments in the Treatment of Peripheral Neuropa

Pirenzepine was never approved for use in the United States by the FDA.

"It had never been used in the US. Uh it was never uh approved here." (said at 0:40:40)

No published record matching the claim that pirenzepine was never approved for use in the United States by the FDA was located; this does not prove the claim false.

0:45:40unverifiedvery lowExciting Developments in the Treatment of Peripheral Neuropa

In a clinical trial in diabetic patients with neuropathy, topical oxybutynin significantly promoted nerve regrowth in the skin compared to placebo.

"The trial was completed. And I think now that I I can say that the cuz we saw efficacy. We we saw that it helped nerves regrow in the skin of diabetic patients significantly... And it could you could measure nerve regrowth in the skin of diabetic patients that didn't happen with a placebo." (said at 0:45:40)

No published record matching a clinical trial demonstrating that topical oxybutynin significantly promoted nerve regrowth in the skin of diabetic neuropathy patients compared to placebo was located; this does not prove the claim false.

Fact-checked episodes

Publications